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We report the molecular identiﬁcation, cloning and initial biological characterization of 12 full-length
HIV-1 subtype A, D and A/D recombinant transmitted/founder (T/F) genomes. T/F genomes contained
intact canonical open reading frames and all T/F viruses were replication competent in primary human
T-cells, although subtype D virus replication was more efﬁcient (po0.05). All 12 viruses utilized CCR5
but not CXCR4 as a co-receptor for entry and exhibited a neutralization proﬁle typical of tier 2 primary
virus strains, with signiﬁcant differences observed between subtype A and D viruses with respect to
sensitivity to monoclonal antibodies VRC01, PG9 and PG16 and polyclonal subtype C anti-HIV IgG
(po0.05 for each). The present report doubles the number of T/F HIV-1 clones available for
pathogenesis and vaccine research and extends their representation to include subtypes A, B, C and D.
& 2012 Elsevier Inc. All rights reserved.Introduction
A globally effective human immunodeﬁciency virus type 1
(HIV-1) vaccine must prevent transmission of widely diverse
virus strains including the less commonly studied subtypes A
and D. Subtypes A and D account for approximately 12% and 2%,
respectively, of all HIV-1 infections worldwide (Hemelaar et al.,
2011), and together with their recombinant forms, are endemic in
East and Central Africa where they co-circulate in the same
regional and ethnic populations (Lihana et al., 2006; Ssemwangall rights reserved.
icine, University of Pennsyl-
hiladelphia, PA 19104-6076,et al., 2012). Interestingly, there have been reports suggesting
that distinct clinical outcomes may be associated with the two
different virus subtypes. For example, compared to subtype A,
subtype D infections have been associated with faster disease
progression (Baeten et al., 2007; Kaleebu et al., 2002; Kiwanuka
et al., 2008; Vasan et al., 2006) and a higher risk for developing
HIV-1 associated neurocognitive disorders (Sacktor et al., 2009).
Infection with subtype D has also been associated with prefer-
ential transmission of CXCR4 (X4) tropic and CXCR4/CCR5 (X4/R5)
dual-tropic viruses (Church et al., 2008), an early co-receptor
tropism switch from R5 to X4 (Kaleebu et al., 2007), a higher
prevalence of X4 strains during chronic infection (Huang et al.,
2007), and a faster rate of CD4þT lymphocyte decline (Kiwanuka
et al., 2010) compared with subtype A infection. Phenotypic
properties of subtype D and A virus strains that might contribute
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reasoned that from both a vaccine and pathogenesis perspective,
a precise molecular identiﬁcation and biological characterization
of molecularly cloned strains of transmitted/founder (T/F) sub-
type A, D and A/D viruses could be informative.
One limitation of previous studies aimed at characterizing
genetic and biological properties of subtype A and D viruses has
been the fact that subtype assignments, diversity measurements
and biological analyses have frequently been conducted on
subgenomic regions of these viruses rather than on full-length
viral genes or genomes (Blish et al., 2007; Church et al., 2008;
Haaland et al., 2009; Kaleebu et al., 2002; Provine et al., 2012;
Redd et al., 2012). Such studies have been further confounded by
the frequent occurrence of unique inter-subtype recombinants
in vivo (Khoja et al., 2008; Lihana et al., 2006; Ssemwanga et al.,
2012) as well as artifactual recombinants that may have been
generated in vitro as a consequence of Taq polymerase DNA strand
switching during the ampliﬁcation of heterogeneous cDNA target
sequences (Salazar-Gonzalez et al., 2008). There is the additional
concern that viral sequences cloned from chronically infected
patients might not reﬂect properties of viruses that result in virus
transmission (Ochsenbauer et al., 2012; Parrish et al., 2012; Wilen
et al., 2011) or could contain sporadic (and unidentiﬁable)
mutations introduced by the most recent HIV-1 reverse tran-
scriptase (RT) step, an RNA Pol II transcription error, or an MuLV
RT error during the cDNA synthesis step prior to PCR ampliﬁca-
tion (Keele et al., 2008). To address these concerns, we sought to
generate a panel of full-length molecularly cloned subtype A, D
and A/D transmitted/founder genomes using single genome
ampliﬁcation (SGA)—direct amplicon sequencing (Keele et al.,
2008; Lee et al., 2009; Salazar-Gonzalez et al., 2009), a strategy
adapted from previously described single genome sequencing
(SGS) methods for analyzing intact HIV-1 pro, pol and env genes
(Palmer et al., 2005; Simmonds et al., 1990). Our laboratory’s
innovation was to use SGS in the context of acute HIV-1 and
simian immunodeﬁciency virus (SIV) infection, together with a
mathematical model of random virus evolution, to infer the exact
nucleotide sequences of T/F virus genomes (Keele et al., 2008,
2009; Lee et al., 2009; Salazar-Gonzalez et al., 2009).
We deﬁne a T/F genome as a viral sequence that is transmitted
and gives rise to productive clinical infection (Keele et al., 2008;
Salazar-Gonzalez et al., 2009). We note that one or more viruses
might breach the cervicovaginal or rectal mucosa or otherwise be
introduced into a naı¨ve individual and fail to replicate or be
extinguished due to early innate immune responses or early
stochastic events in the transmission process (Pearson et al.,
2011). Such viruses are of no consequence to the present study
since they do not lead to productive clinical infection. We also
note that a ‘transmitted’ virus genome and a ‘founder’ virus
genome from which subsequent genomes evolve may or may
not be identical. For example, in the case of HIV-1 or SIV, the
transmitted viral RNA genome must ﬁrst undergo reverse tran-
scription in order to productively infect the ﬁrst cell in the naı¨ve
host. It is thus possible that the DNA provirus in this cell differs
from the infecting viral RNA genome by either point
mutation(s) or recombination event(s). The former are expected
to occur with a frequency of about 2.26105, or about 0.2 muta-
tions per 10 kb genome per infection event (Keele et al., 2008; Lee
et al., 2009; Mansky and Temin, 1995). The latter are also
common and potentially signiﬁcant when the diploid viral RNA
genome is heterozygous (Keele et al., 2008, 2009; Lee et al., 2009).
RT mediated vRNA strand transfers (recombination) can occur
multiple times with each reverse transcription event but are
generally not apparent unless the virus genome is heterozygotic
or polymerase slippage occurs resulting in sequence deletion or
duplication (Levy et al., 2004). To account for these differentpossibilities, we use the term ‘transmitted/founder’ genome to
describe the viral genome that is transmitted and leads to
productive clinical infection. We also make the important dis-
tinction between T/F virus genomes derived by single genome
sequencing methods and that are identical to actual founding
virus genomes at or near the moment of transmission, and ‘‘early’’
or ‘‘near-transmitted/founder’’ sequences derived by non-SGS
techniques that are susceptible to Taq polymerase-mediated
in vitro recombination, founder effects, and ambiguities arising
from population sequencing, cloning-sequencing strategies, and
in some studies, short-term virus culture effects (Aasa-Chapman
et al., 2006; Blish et al., 2007; Coetzer et al., 2008; Derdeyn et al.,
2004; Isaacman-Beck et al., 2009; Nedellec et al., 2009;
Quakkelaar et al., 2007; Sagar et al., 2009, 2003; Seaman et al.,
2010).
To pursue the identiﬁcation and cloning of full-length subtype
A, D and A/D T/F virus genomes, investigators representing the
Center for HIV/AIDS Vaccine Immunology (CHAVI), the Interna-
tional AIDS Vaccine Initiative (IAVI) and the Uganda Virus
Research Institute/Medical Research Council/Wellcome Trust col-
laborated in a molecular survey of incident HIV-1 infections in
Uganda, Kenya and Rwanda with the goal of identifying acutely
infected subjects at early Fiebig stages (Fiebig et al., 2003). HIV-1
negative high risk commercial sex workers, men who have sex
with men and HIV-1 serodiscordant co-habitatiing couples were
serially tested for antibody seroconversion. Testing was monthly
or quarterly, and those individuals who became infected were
offered enrollment into IAVI protocol C, which called for frequent
blood draws for HIV-1 research. Because identiﬁcation of T/F viral
sequences depends on a phylogenetic analysis of very early viral
sequences that undergo essentially random diversiﬁcation (i.e.,
prior to the onset of adaptive immune responses that select for
escape mutants) (Goonetilleke et al., 2009; Keele et al., 2008;
Salazar-Gonzalez et al., 2009), we tested plasma specimens
corresponding to the ﬁrst ELISA HIV antibody positive time point
by western immunoblot so as to determine the clinicopathologi-
cal stage of acute HIV-1 infection as described by Fiebig et al.
(2003). For subjects with later stages of acute infection (Fiebig
stages V and VI), we tested the preceding antibody negative
sample for HIV-1 vRNA, hoping to identify subjects in the earliest
vRNAþ/Ab stages (Fiebig Stage I–II). The primary objectives of
the present study were: (i) to determine if in the setting of
observational ﬁeld studies in Central and East Africa, we could
identify patients and clinical samples amenable for a precise and
unambiguous molecular identiﬁcation of full-length T/F viral
genomes; (ii) to molecularly clone and validate the replication
competence of such T/F genomes and to assess their basic genetic
and phenotypic characteristics; and (iii) to contribute subtype A
and D clones and sequences to HIV/AIDS reagent and sequence
repositories to encourage vaccine and pathogenesis research on
these relatively neglected HIV-1 subtypes.Results
Study subjects
Between October 2004 and February 2009, 165 subjects
participating in IAVI vaccine preparedness studies, 14 subjects
in the Uganda Virus Research Institute/Medical Research Council/
Wellcome Trust HIV high risk cohort, and two subjects from an
HIV discordant couple study seroconverted to HIV-1 antibody
positivity were evaluated for inclusion in the current study.
On the basis of specimen availability, serological data indicating
very recent infection, virus load and specimen integrity, we
selected 12 subjects for in-depth analysis. Six subjects were at
Table 1
Socio-demographic, clinical and laboratory characteristics of study subjects.
Volunteer
ID
Trans-
mission
type
Country
sample
Sampling
date
Clinical
specimen
Viral load
RNA
copies/ml
ELISA Western blot Fiebig
stage
R880F MTFa Rwanda 1/12/07 PBMC/Plasma 430,843 Reactive Negative III
R463F MTF Rwanda 3/9/07 PBMC/Plasma 150,000,000 Reactive Indeterminate IV
191084 MTF Uganda 3/27/07 PBMC/Plasma 34,600 Reactive Indeterminate IV
191845 MTF Uganda 4/5/07 Plasma 31,200 Reactive Indeterminate IV
9004SS FTM Uganda 5/17/07 Plasma 29,921 Reactive Indeterminate IV
191727 MTF Uganda 1/24/07 Plasma 15,200 Reactive Indeterminate IV
190049 MTF Uganda 6/21/05 Plasma 38,266,666 NRb Negative II
191647 FTM Uganda 2/5/07 Plasma 242,222 NR Negative II
191859 MTF Uganda 2/12/08 Plasma 53,334 NR Negative I
191882 FTM Uganda 12/12/07 Plasma 15,378 NR Negative I
191947 FTM Uganda 9/11/07 Plasma 5,466 NR Negative I
191982 MTF Uganda 5/28/08 Plasma 7,156 NR Negative I
a MTF—Male to female, FTM—Female to male.
b NR—Non-reactive.
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infection. Eight subjects were female and four were male. Two
subjects were from Rwanda and ten were from Uganda. Other
demographic and clinical information is as listed (Table 1).
Diversity analysis
SGA-direct amplicon sequencing was used to derive 160 50 and
201 30 overlapping half genome sequences from plasma viral RNA
of 10 subjects. For two additional subjects, R880F and R463F,
sequencing of twenty-two 9-kb single genome-derived amplicons
was performed. Maximum likelihood trees of 50 and 30 half
sequences from all 12 subjects showed that viral sequences from
each subject formed monophyletic lineages with no interspersion of
sequences (Fig. 1A and B). Sequences from ﬁve subjects clustered
with reference subtype A viruses in both 50 and 30 trees, and
sequences from ﬁve other subjects clustered with reference subtype
D viruses in both genomic regions. Recombination identiﬁcation
program (RIP) (http://www.hiv.lanl.gov/content/sequence/RIP/RIP.
html) and REGA HIV-1 subtyping (http://dbpartners.stanford.edu/
RegaSubtyping/) analyses of these sequences compared to A and D
reference sequences showed them to be non-recombinants. The 50
and 30 half genome sequences of two subjects, 191947 and 191982,
clustered inconsistently with subtype A and D reference sequences
suggesting that these T/F viruses likely represented inter-subtype
A/D recombinants. A formal recombination analysis of full-length
genomes from these subjects revealed them to be unique complex
A/D recombinants (see below).
In 11 of 12 subjects, maximum within-patient sequence diver-
sities were low ranging from 0.02% to 0.5% and 0.05% to 0.19% for
the 50 and 30 half sequences, respectively (Table 2). Such low
sequence diversity is generally indicative of single variant transmis-
sion based on model estimates and empirical observations of the
rate of diversiﬁcation of HIV-1 over the initial 100 days of infection
(0.60%, 95% CI 0.54–0.68%) (Keele et al., 2008). However, transmis-
sion of two or more closely related viruses cannot be discriminated
by this diversity cutoff value (Keele et al., 2008), and phylogenetic
trees and Highlighter plots suggested that one of the 11 of subjects
(191084) with relatively homogeneous sequences was actually
productively infected by a minimum of two closely related viruses.
A twelfth subject (191727) had a high maximum within-patient
diversity of 1.54% and phylogenetic evidence indicated productive
infection by at least three distinct T/F viral lineages (Fig. 1). We note
that for the purposes of identifying examples of T/F full-length
genomes, the numbers of sequences per subject that we analyzed
(between 10 and 51 half-genomes) (Table 2) were sufﬁcient to
unambiguously infer consensus founder sequences. However, thisnumber is not sufﬁcient for estimating with precision the total
number of T/F virus genomes per subject, and thus the numbers of
T/F viruses that we identiﬁed (median¼1; mean¼1.25; range¼1–
3) must be considered minimum estimates (Table 2).
Identiﬁcation of T/F HIV-1 genomes
HIV-1 transmission at mucosal surfaces is characterized by a
stringent population bottleneck that in most instances results in
one or few variants out of many establishing productive clinical
infection (Abrahams et al., 2009; Derdeyn et al., 2004; Haaland
et al., 2009; Keele et al., 2008; Salazar-Gonzalez et al., 2009). The
goal of the present study was to identify and clone one full-length
T/F genome from each of the 12 subjects. Fig. 2A—C show
Highlighter plots of 50 and 30 half genome sequences from subjects
190049 and 181845 and near full-length sequences for subject
R463F. For these three subjects, the proportion of sequences
identical to the respective consensus sequence ranged from 30%
(R463F) to 67% (190049–30 genome) and all variants differed from
the respective consensus by just 1 to 3 randomly distributed
mutations. Thus, for these three subjects, the consensus sequence
is readily inferred to be the T/F sequence. Fig. 2D shows a similar
pattern of early virus diversiﬁcation in subject R880FPL but with
the added feature of a shared nucleotide polymorphism at
position 8900. Sequences from other subjects sometimes had
shared polymorphisms in just two sequences (R880FPB; 191982;
191882) and sometimes more (191882; 191859) (see Sﬁgure 1 in
Supplementary material). Shared polymorphisms like these com-
monly arise due to early stochastic mutations that occur during
the ﬁrst one or few replication cycles following virus transmission
(Lee et al., 2009) and it may not be possible to determine which
variant was actually transmitted. Regardless, both sets of
sequences are extremely closely related (generally differing by
only one or few nucleotides per 10 kb), both are ﬁt for replication,
and both meet the operational deﬁnition of a T/F genome. For
these subjects, we generally selected the overall consensus as the
T/F virus genome, unless sequences were available from a sexual
partner that indicated the likely transmitted allele. For some
subjects, we had serial samples for analysis (191947; 191647).
Sequential samples can reveal which sequences are best ﬁt to
replicate over time and oftentimes show sequence diversiﬁcation
suggesting immune selection (Goonetilleke et al., 2009; Salazar-
Gonzalez et al., 2009). The latter changes can facilitate a distinc-
tion between a transmitted genome and mutant sequences
arising from it.
Sequences from subject 9004SS were more complicated to
analyze because there was a shared sequence polymorphism at
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Fig. 1. Maximum likelihood phylogenetic trees of 50 (A) and 30 (B) half genome sequences from 12 acutely infected subjects. HIV-1 reference and T/F sequences are labeled
in green for subtype A, blue for subtype D, and red for A/D recombinants. Subtype B and C reference sequences are labeled in black. The scale bars represent 1% genetic
distance.
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Table 2
Diversity analysis of SGA sequences and genotypic characteristics of infectious molecular clones.
Volunteer
ID
Clone ID Subtype No. of
SGAa
Maximum
nt lengthb
Maximum
diversity (%)
No. of
transmitted/
founder
viruses
IMCc V3
charged
IMC gp41
length
IMC TAT
exon 2
IMC genome
lengthe
RE sites
(5’, 3’)f
Cloning
vector
50 30 50 30 50 30
R880F pR880F A 10 12 4448 4643 0.05% 0.10% 1 1.8 477 Full length 9729 SpeI, MluI pCR XL
TOPO
R463F pR463F A 10 10 4216 4629 0.09% 0.04% 1 1.8 477 Full length 9739 NotI, MluI pCR XL
TOPO
191084 p191084 A 11 10 4381 4612 0.35% 0.17% 2 3.7 456 Full length 9701 MluI, XhoI pBR322
191845 p191845 A 13 13 4416 4720 0.15% 0.05% 1 3.8 477 Full length 9854 MluI, NotI pCR XL
TOPO
9004SS p9004SDM A 11 13 4454 4639 0.07% 0.10% 1 3.8 477 Full length 9725 MluI, NotI pCR XL
TOPO
191727 pSC191727 D 31 51 4359 4618 0.30% 1.54% 3 1.8 456 Truncated 9715 NotI, XhoI pBR322
190049 p190049 D 22 21 4412 4564 0.10% 0.07% 1 2.8 456 Full length 9674 MluI, NotI pCR XL
TOPO
191647 p191647 D 19 23 4390 4567 0.37% 0.12% 1 3.8 456 Truncated 9653 MluI, NotI pCR XL
TOPO
191859 p191859 D 12 21 4403 4646 0.12% 0.14% 1 2.8 456 Truncated 9763 MluI, NotI pCR XL
TOPO
191882 p191882 D 17 18 4398 4570 0.42% 0.10% 1 1.8 456 Full length 9792 MluI, NotI pCR XL
TOPO
191947 p191947 A/D 12 16 4413 4665 0.07% 0.12% 1 3.8 477 Full length 9710 MluI, NotI pCR XL
TOPO
191982 p191982 A/D 13 17 4392 4617 0.50% 0.19% 1 0.8 456 Truncated 9778 MluI, NotI pCR XL
TOPO
a Single genome amplicons.
b Maximum 50 and 30 sequence nucleotide (nt) lengths span overlapping HIV-1 genomic segments corresponding to HXB2 nt positions 582-5039 and 4984-9606.
c Infectious molecular clone.
d V3 charge at pH 7.5.
e IMC genome lengths include all HIV-1 genes and complete 50 and 30 LTR elements.
f Restriction enzyme sites appended to 50 and 30 ends, respectively.
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sequences (Fig. 3). To determine which allele was transmitted
and which was acquired, we examined sequences from an
epidemiologically-linked sexual partner. We found that the min-
ority sequence polymorphism present in three of eleven 50
sequences in the initial 9004SS sequence set was the only
detectable allele present in the sexual partner, thus allowing for
an unambiguous determination of the T/F sequence as shown
(Fig. 3). For subject 191084, there were several sets of shared
mutations in the 30 half-genome variant 1 sequences (boxed in
Fig. 4A). These shared mutations are indicated in Fig. 4B where
each set is observed to occur in one of two short stretches of 9 or
fewer amino acids in Nef. Sequence toggles like these have been
described previously and generally represent cytotoxic T-cell
epitope escape mutations (Goonetilleke et al., 2009; Keele et al.,
2008; Salazar-Gonzalez et al., 2009). By examining the timing and
directionality of such mutations, it is possible to infer the likely
T/F sequence and the evolving escape mutations derived from it.
Finally, for subject SC191727 (Fig. 5), SGS allowed us to decipher
at least three T/F lineages along with multiple unique inter-
lineage recombinants, and from the predominant T/F lineage we
could readily infer an unambiguous T/F sequence. However, this
required that we amplify an additional 3 kb fragment spanning
the pol and vpu genes to conﬁrm the linkage of 50 V1 and 30 V1
consensus genomes (Fig. 5).
The 12 T/F genomes ranged in length from 9653 to 9854 nt
(Table 2) and had intact open reading frames for the canonical
HIV-1 genes gag, pol, pro, int, vif, vpr, vpu, tat, rev, env and nef.
Five T/F genomes were entirely A subtype and ﬁve were entirely
D subtype. Two genomes had evidence of recombination between
A and D subtypes. We employed SimPlot and maximum likelihood
phylogenetic analytical tools to characterize the recombinationbreakpoint locations to distinguish unique from circulating recom-
binant form viruses. Using the 2010 subtype reference sequences,
both SimPlot and maximum likelihood phylogenetic analyses con-
curred in different subtype assignments for the sub-genomic
segments of 191947 and 191982 T/F genomes (Fig. 6). Both
genomes were found to be complex unique subtype A and D
recombinant forms as shown. The two viruses each contained
subtype A gp120 Env and Vif sequences, but otherwise contained
essentially antithetical distributions of A and D sequences.
We also noted salient subtype speciﬁc genetic polymorphisms
in the envelope gp41 and tat exon 2 among the T/F subtype A and
D genomes. All ﬁve subtype D and one A/D recombinant (191982)
T/F genomes had a conserved seven amino acid deletion in the a-
helical amphipathic lentivirus lytic peptide (LLP) 2 domain
(between g41 amino acid position 268–279; HXB2 numbering).
One subtype A T/F genome, 191084, was distinct in having a
seven amino acid truncation of the C-terminal LLP-2 domain at a
position immediately adjacent and downstream of the subtype D
deletion. Three of ﬁve subtype D (191727, 191647 and 191859)
and one A/D recombinant (191982) genomes had a truncated tat
exon 2 compared to none of ﬁve clade A genomes, resulting in a
loss of 16 amino acids. V3 loop charges of subtype A, D and A/D T/
F genomes V3 sequences at pH 7.5 were generally low, ranging
from 0.8 to 3.8, typical of R5 tropic virus strains (Balasubramanian
et al., 2012; De Wolf et al., 1994; Kaleebu et al., 2007).Molecular cloning of subtype A, D and A/D T/F genomes
T/F genomes were cloned into either pCR XL TOPO or pBR322
plasmid vectors at the restriction sites indicated (Table 2). The
nucleotide sequences of the T/F clones were deposited in Genbank
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Fig. 2. Highlighter (www.HIV.LANL.gov) plots of 50 and 30 half genomes or near full-length sequences for subjects 190049 (A), SC191845 (B), R463F (C) and R880FPB (D). Tic
marks represent nucleotide substitutions as compared to the top-most T/F sequence in each plot. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
J. Baalwa et al. / Virology 436 (2013) 33–4838(accession numbers JX236668–JX236679) and at http://www.hiv.
lanl.gov/content/sequence/HIV/USER_ALIGNMENTS/Baalwa/.
Phenotypic characterization of molecularly cloned T/F viruses
Although T/F HIV-1 genomes are expected to be replication
competent since their sequences correspond to founder virusesthat are responsible for productive clinical infection in humans,
assaying virus replication is a key test of the T/F concept and the
integrity of the T/F molecular virus clones. We thus tested the
molecularly cloned viral genomic DNA corresponding to all 12 T/F
viruses for replication competence in primary human CD4þ
T-cells. T/F DNA was transfected and expressed in 293T cells
and resulting virus was passaged cell-free onto activated primary
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J. Baalwa et al. / Virology 436 (2013) 33–48 39human CD4þT lymphocytes from three different normal donors
(Fig. 7A–C). All 12 viruses replicated relatively efﬁciently with
kinetics generally comparable to the subtype B control virus SG3
and historical controls (Ochsenbauer et al., 2012; Salazar-
Gonzalez et al., 2009) and with peak p24 antigen concentrations
of 100–1000 ng/ml or higher. Interestingly, there was a statisti-
cally signiﬁcant trend (po0.05) for subtype D viruses to replicate
more rapidly and to higher titers compared with subtype
A viruses (Fig. 7D). This was a reproducible ﬁnding in different
experiments, conducted on different days, at different multipli-
cities of infection (Fig. S2) and using CD4þT-cells from different
normal human donors.
We next tested T/F subtype A, D and A/D viruses for use of the
chemokine coreceptors CCR5 and CXCR4, anticipating possibly
that there might be a predilection for T/F D subtype viruses to use
CXCR4 based on previous literature reports of subtype D virus
isolates (Huang et al., 2007; Kaleebu et al., 2007). Whereas
AMD3100, a selective inhibitor of CXCR4 mediated entry, com-
pletely inhibited the entry of the control X4 tropic virus SG3, it
had no effect on any of the 12 T/F viruses (Fig. 8A). Conversely, the
CCR5 inhibitor TAK-779, inhibited the entry of the control R5
tropic virus YU2 and all T/F viruses. These ﬁndings suggested that
CCR5 and not CXCR4 was the predominant co-receptor for virus
entry by these T/F viruses. These ﬁndings were corroborated by
analyses in NP2 cells that express CD4 and either CCR5 or CXCR4
but not both. Here again we found all 12 T/F viruses used CCR5
but not CXCR4 for cell entry (Fig. 8B).
Finally, we assayed the T/F viruses as IMCs or as Env-
pseudotyped viruses for sensitivity to neutralization by pooled
heterologous polyclonal HIV immunoglobulins from subtype B
(HIVIG-B) or C (HIVIG-C) infected donors, by polyclonal IgG
antibodies from each of three HIV-1 subtype C infected subjects
previously shown to have broad and potent neutralizing anti-
bodies, by the broadly neutralizing human monoclonal antibodies
b12, VRC01, 2G12, 2F5, 4E10, PG9 and PG16, and by the fusion
inhibitor T-1249 (Table 3). Interestingly, there was a trend for the
subtype D virus Envs to be more resistant to HIVIG-C (P¼0.045)
and HIVIG-B (P¼0.059) than were subtype A Envs. Similarly, fourout of ﬁve subtype D Envs were not neutralized by any of the
3 heterologous IgG polyclonal antibodies (SA-C62, SA-C72 and
SA-C74) at IgG concentrations as high as 2500 mg/ml, while all
subtype A Envs were neutralized at concentrations (IC50) ranging
from 226 to 1997 mg/ml (p¼0.139, 0.0007 and 0.052, respec-
tively). The 12 T/F viruses were variably sensitive to the mem-
brane proximal external region (MPER) speciﬁc mAb 4E10 and
2F5. Interestingly, all ﬁve T/F subtype A viruses were sensitive to
neutralization by VRC01 (mean IC50¼1.75 mg/ml) and extremely
sensitive to PG9 (mean IC50¼0.05 mg/ml) and to PG16 (mean
IC50¼0.003 mg/ml). This was not the case for subtype D T/F
viruses, most of which exhibited resistance to these mAbs with
IC50 values exceeding 10 mg/ml (p¼0.049, 0.004 and 0.0001,
respectively). Conversely, subtype A viruses were pan-resistant
to b12 (IC50410 mg/ml) whereas 3 of 5 subtype D viruses were
sensitive (mean IC50¼5.69 mg/ml; p¼0.058). The A/D recombi-
nant viruses, which contain subtype A gp120 segments, exhibited
neutralization patterns similar to subtype A T/F viruses. Subtype
A, D and A/D viruses, like subtype B and C T/F viruses (Keele et al.,
2008; Salazar-Gonzalez et al., 2009), were comparably sensitive
to the gp41 reactive fusion inhibitor T-1249.Discussion
The concept of identifying full-length T/F virus genomes by
SGS is a relatively new idea with numerous research applications
in HIV/SIV research as well as for other viral systems. To our
knowledge, there are only four reports in the scientiﬁc literature
describing full-length HIV-1 T/F genomes and these are limited to
subtypes B and C (Li et al., 2010; Ochsenbauer et al., 2012; Parrish
et al., 2012; Salazar-Gonzalez et al., 2009). This approach has been
widely adopted, since it makes possible a sensitive molecular
probing and analysis of virus-host interactions operative at or
near the moment of virus transmission, during the eclipse phase
when virus replicates extensively but is not yet detectable in the
plasma, and later when virus begins to diversify under host
immune pressures (Bar et al., 2012; Goonetilleke et al., 2009).
Fig. 4. (A) Highlighter plots of 50 and 30 half genome sequences for subject 191084 infected with two very closely related viruses evident in 30 sequences. Boxed mutations are
represented in panel B below. (B) A partial Nef amino acid alignment of the inferred variant 1 T/F sequence and the month 2, 3, 6 and 9 post-seroconversion sequences is shown.
The 191084PSTF sequence was derived from proviral DNA in peripheral blood mononuclear cells whereas all other sequences were derived from plasma viral RNA. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Baalwa et al. / Virology 436 (2013) 33–4840New insights obtained by this approach include: (i) enumeration
of T/F viral genomes responsible for productive clinical infection,
which in heterosexuals is generally one, in homosexuals slightly
higher, and in intravenous drug users higher still, sometimes
involving 10 or more transmitted viruses (Bar et al., 2010; Keele
et al., 2008; Li et al., 2010); (ii) biological characterization of T/F
subtype B and C viruses resulting from mucosal transmission,
which revealed CCR5 but not a4b7 tropism (Parrish et al., 2012;
Wilen et al., 2011) as well as occasional use of alternative (non-
CCR5/CXCR4) co-receptors (Jiang et al., 2011); (iii) antigenic
characterization of T/F viruses revealing uniformly tier 2 or 3 level
neutralization resistance typical of primary virus isolates (Keele
et al., 2008; Li et al., 2010); (iv) failure of subtype B or C T/F
viruses to replicate efﬁciently in macrophages compared with
primary CD4þ T lymphocytes (Li et al., 2010; Ochsenbauer et al.,
2012; Salazar-Gonzalez et al., 2009); (v) rapid evolution of CTL
escape mutations (or reversions) away from the T/F proteome in
the days and weeks following transmission followed weeks later
by neutralizing antibody escape (Bar et al., 2012; Goonetillekeet al., 2009); and (vi) immunologically-mediated sieving of
viruses in phase III human vaccine trials (de Souza et al., 2012;
Rolland et al., 2011). These ﬁndings highlight the enabling
potential of T/F virus genome characterization and led us to
pursue the analysis of T/F viruses for two less well studied HIV-
1 subtypes A and D.
In our ﬁeld survey of incident HIV-1 infections in Central and
East Africa, we were able to identify discrete low diversity
sequence lineages emanating from T/F viral genomes in each of
12 subjects in early stages of infection (Fiebig I–IV). Four of the
earliest stage subjects (Fiebig I) had plasma viral loads between
7000 and 53,000 per milliliter representing early ramp-up vir-
emia. But even in Fiebig Stage IV patients, we could identify T/F
sequence lineages. Ten of 12 subjects had evidence of transmis-
sion of a minimum of one virus and two others had evidence of
infection by at least two or three viruses. These are minimal
estimates consistent with an extensive body of published data on
hundreds of acutely infected subtype B and C subjects that
suggest that the multiplicity of HIV-1 infection resulting from
Fig. 5. Neighbor-joining tree phylogenies and Highlighter plots of 50 and 30 half genome sequences for subject 191727. T/F variants (v1-3) and recombinant (Rec) sequences
are indicated. Amplicon sequences (N14, N6, N1 and N4) at the bottom of both panels that bridge the 50 and 30 half genome sequences show homology with lineage V1.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Baalwa et al. / Virology 436 (2013) 33–48 41sexual transmission is generally one, although the range can
reach as high as 10 or more (Abrahams et al., 2009; Haaland
et al., 2009; Keele et al., 2008).
With the exception of shared stochastic mutations and one
example of likely immune selection (Fig. 4; subject 191084),
acute sequences emanating from discrete T/F genomes followed
a pattern of essentially random variation with a near star-like
phylogeny and a Poisson distribution of low frequency mutations
indistinguishable from earlier ﬁndings with subtypes B and C (Li
et al., 2010; Ochsenbauer et al., 2012; Salazar-Gonzalez et al.,2009). This observation gives validation to the conclusion that the
sequences identiﬁed in the present study as T/F genomes are
genuine. Also consistent with this interpretation is the fact that all
potential reading frames for all viruses were open, and each T/F
virus was replication competent in activated human CD4þT cells.
Whether the modestly enhanced replicative properties of subtype
D viruses compared with subtypes A viruses contributes to the
clinical observations of enhanced subtype D pathogenicity
described previously will require much more detailed analyses
of additional viruses and comparative studies of virus biology.
Fig. 6. Recombination analysis of T/F viruses from 191982 and 191947. Different phylogenetic assignments for different genomic segments of 191982 (A) and 191947 (B)
are shown in maximum likelihood phylogenetic trees corresponding to sequence regions mapped on the HIV-1 genome below. Numbers above trees and at breakpoints are
HXB2 coordinates. Letters at branch tips indicate subtype reference sequences. Branches for subtypes A and D are shown in green and blue, respectively. Branches for
recombinants are shown in red. Asterisks indicate branches for subtypes withZ70% bootstrap support. Breakpoint locations are based on maximal X2 values for
informative sites determined using SimPlot are shown by HXB2 coordinates. Boxes in the HIV-1 genome map represent the subtype assignments: subtype A, green;
subtype D, blue. For segment 4236-5045, the 191982 sequence clusters signiﬁcantly with another reference D sequence but the B sequence grouping nests within other D
sequences, leading to phylogenetic ambiguity in this region.
J. Baalwa et al. / Virology 436 (2013) 33–4842
Fig. 7. Analysis of T/F virus replication in primary human CD4þT cells. CD4þ T cells from three normal blood donors (A–C)were infected with T/F genome derived viruses
at an M.O.I of 0.1. The replication kinetics of T/F viruses are shown relative to the prototypic viral clone SG3 (black dashed lines). Values on the y-axis denote ng per ml of
p24 antigen and the x-axis days post-infection. (D) Comparison of replication kinetics of 5 subtype A with 5 subtype D T/F viruses is shown. Data points and error bars
indicate mean and standard deviation. Statistical analysis was performed using the Mann–Whitney test and two-tailed p-values are shown. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Baalwa et al. / Virology 436 (2013) 33–48 43One important direction for future work will be on macrophage
versus lymphocyte tropism of subtype D and A viruses and the
ability of these viruses to replicate in cells bearing low levels of
CD4 or alternative coreceptors in order to explore potential
predilections of subtype D viruses for neurovirulence. This work
is beyond the scope of the present study but is a potentially
fruitful area of research.
One of the interesting ﬁndings of this study was the subtype-
associated genetic polymorphisms between subtype A and D T/F
genomes. We found that all ﬁve clade D genomes and one A/D
recombinant genome had a highly conserved seven amino acid
deletion within the amphipathic alpha-helical LLP-2 domain of
the envelope intra-cytoplasmic tail compared to the ﬁve clade A
genomes. A comparison of T/F genomes with subtype A, B, C and
D HIV-1 reference sequences from the HIV Sequence Compen-
dium 2011 (Kuiken et al., 2012), revealed that all subtype B and D
sequences, but not subtype A or C sequences, shared this highly
conserved deletion. The LLP 1, 2 and 3 domains have been shown
to modulate HIV-1 envelope expression, incorporation, viral
infectivity and virally-mediated cell-cell fusion (Bhakta et al.,
2011; Kalia et al., 2003; Lambele et al., 2007; Lu et al., 2008;
Steckbeck et al., 2011; Wyss et al., 2005). Interestingly, trunca-
tions that shorten the LLP2 domain have been shown to enhance
fusion efﬁciency (Wyss et al., 2005). We also found that three of
ﬁve subtype D genomes and one A/D recombinant genome had apremature truncation of the second exon of tat resulting in the
loss of sixteen amino acids. This tat polymorphism has been
previously observed among some subtype B HIV-1 strains includ-
ing HXB2, and there is conﬂicting evidence on the role of the
second tat exon in viral replication (Guo et al., 2003; Mahlknecht
et al., 2008; Neuveut et al., 2003). The other notable ﬁnding was
the similarity in V3 loop positive charge between subtype A
(mean¼þ3.0, SD¼1.1) and D (mean þ2.6, SD¼0.8; p40.5) T/F
genomes, which differs from previous studies that suggested that
subtype D strains were likely to possess higher V3 loop positive
charge than subtype A (De Wolf et al., 1994; Kaleebu et al., 2007).
However, the sample size in our study is too low to extrapolate
our ﬁndings; instead, our study provides naturally-occurring,
clinically relevant T/F viral reagents for further biological analysis.
The antigenic properties of subtype A and D viruses are of
interest since a broadly effective vaccine will need to protect
against infection by these genetically diverse virus strains. A
principal observation was that compared to subtype A, subtype
D Env pseudoviruses as a group tended to be more resistant to
neutralization by heterologous pooled immunoglobulins (HIVIG-B
and HIVIG-C) and by broadly neutralizing polyclonal IgG antibo-
dies isolated from individual HIV-1 subtype C infected patients.
This ﬁnding was intriguing and suggests that vaccine immunogens
based on subtype B and C Envs might induce less effective
immunity against subtype D viruses. The 12 T/F viruses were
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J. Baalwa et al. / Virology 436 (2013) 33–4844widely variable in their sensitivity to the MPER-speciﬁc mAbs
4E10 and 2F5, and this could not be simply explained by sequence
variation in the canonical epitopes (Blish et al., 2007; Zwick et al.,
2005). Interestingly, all ﬁve T/F subtype A viruses were extremely
sensitive to PG9 and PG16, which was not the case for subtype D
viruses, but again this could not be simply explained by sequence
variation in these canonical epitopes (Walker et al., 2009). Con-
versely, subtype A viruses were pan-resistant to b12 whereas 3 of
5 subtype D viruses were sensitive. These neutralization proﬁles of
subtype A, D, and A/D viruses may reﬂect the derivation of PG9
and PG16 mAbs from a subtype A donor and b12 from a subtype B
donor, since subtypes B and D are more closely related phylogen-
etically than are subtypes B and A (Dwivedi and Sengupta, 2012).
Much remains to be explored concerning the transmission
biology, immunopathogenesis, and prevention strategies for HIV-
1 subtypes A and D. The molecular identiﬁcation and cloning of
J. Baalwa et al. / Virology 436 (2013) 33–48 45full-length T/F HIV-1 genomes by SGS takes a step toward these
goals by taking advantage of the natural virus population bot-
tlenecking that occurs with virus transmission from one indivi-
dual to the next, thus ensuring that the cloned genome represents
a biologically and clinically relevant T/F virus unaltered by in vitro
cultivation, selective ampliﬁcation, or Taq polymerase, RNA Pol II
or MuLV RT mutational errors. The 12 subtype A, D, and A/D T/F
genomes reported here double the number of HIV-1 subtypes for
which T/F genomes have been derived and double the number of
T/F virus genomes available for analysis. This work can facilitate a
systematic molecular analysis of genome-wide structure, func-
tion, antigenicity and immunogenicity of these clinically impor-
tant viruses and virus subtypes. Beyond this, the identiﬁcation
and cloning of other highly variable single-stranded T/F RNA (or
DNA) viruses including, for example, the Flaviviridae represent an
important new research opportunity (Li et al., 2012).Methods and materials
Study subjects
Subjects were enrolled in IAVI-sponsored prospective vaccine
preparedness cohort studies of HIV-1 antibody negative hetero-
sexuals or men who have sex with men (Price et al., 2012, 2011;
Tang et al., 2011), in a Uganda Virus Research Institute/Medical
Research Council/Wellcome Trust HIV-1 acquisition cohort study,
and in a heterosexual sero-discordant couples cohort study in
Rwanda (Derdeyn et al., 2004). Subjects were given HIV counsel-
ing, condom provision and regular HIV testing either monthly or
quarterly. Those who seroconverted to HIV-1 were screened for
stage of primary HIV-1 infection and those between Fiebig Stage I
to IV were included in the present study if sufﬁcient cryopre-
served plasma and/or peripheral blood mononuclear cells
(PBMCs) were available for analysis and if viral loads and vRNA/
cDNA integrity were sufﬁcient for SGA analysis. The guideline for
laboratory staging of primary HIV-1 infection (Fiebig staging) has
been described elsewhere (Fiebig et al., 2003; Keele et al., 2008).
All subjects gave informed consent and blood specimen collec-
tions were undertaken with institutional review board and other
regulatory approvals.
Proviral DNA extraction, viral RNA isolation and cDNA synthesis
Plasma viral RNA (vRNA) and proviral DNA were extracted
from blood specimens using the QIAamp RNA or DNA Mini Kits
(Qiagen, Valencia, CA) as previously described (Keele et al., 2008;
Salazar-Gonzalez et al., 2009). Reverse transcription was per-
formed using Superscript III (Invitrogen) according to the manu-
facturer’s instructions in two steps. First, 30 ml of RNA were mixed
with 0.5 mM of each deoxynucleoside triphosphate (dNTP) and
0.25 mM of reverse primer 1.R3B3R (50-ACTACTTGAAGCACT-
CAAGGCAAGCTTTATTG-30), reconstituted in a volume of 36 ml
and incubated at 65 1C to denature RNA secondary structure.
Second, 24 ml of an RT reaction mix consisting of ﬁrst strand RT
buffer (1X), 5 mM dithiothreitol, 2 U/ml of RNase inhibitor-RNase
OUT and 5 U/ml Superscript III was added to the ﬁrst mix, bringing
the total reaction volume to 60 ml, which was then incubated at
50 1C for 80 min. The RT reaction was then terminated by
incubation at 85 1C for 5 min, followed by the addition of 3 ml of
RNase H and a ﬁnal incubation at 37 1C for 20 min to denature the
RNA strands. The reverse primer 1.R3B3R was used to synthesize
cDNA templates for full-length and 30 half genome ampliﬁca-
tion. To synthesize cDNA templates for ampliﬁcation of the 50
genomic half, the same RT protocol was followed but using B5R1
(50-CTTGCCACACAATCATCACCTGCCAT-30; nt 5052–5077) as thereverse primer. The synthesized cDNA was either used immedi-
ately or stored at 80 1C.
Single genome ampliﬁcation
cDNA was serially diluted with each dilution replicated in 12
wells and ampliﬁed by nested PCR. cDNA dilutions found to result
in 30% or fewer PCR positive wells were adopted to obtain
additional amplicons using 96-well reaction plates. Two
approaches were used to derive single genome amplicons. In
one approach, 9 kb genomes extending from 50U5 to 30U3-R
were ampliﬁed as previously described (Keele et al., 2008;
Salazar-Gonzalez et al., 2009). Brieﬂy, ﬁrst round PCR was carried
out in the presence of 1 Expand Long template buffer contain-
ing MgCl2 at a ﬁnal concentration of 1.75 mM, 0.35 mM of each
dNTP, 0.3 mM of each primer and 3.75 u/ml of expand long
template enzyme mix (Roche) in a 50 ml reaction. First round
primers were: forward-U5Cc (50-CCTTGAGTGCTCTAAGTAGTG-
TGTGCCCGTCTGT-30) and the reverse primer 1.R3B3R. The second
round PCR primers were: forward-U5Cd (50-AGTAGTGTGTGC-
CCGTCTGTTGTGTGACTC-30) and reverse-2.3030plCb (50-TAGAG-
CACTCAAGGCAAGCTTTATTGAGGCTTA-30). PCR conditions were:
94 1C for 2 min, followed by 10 cycles of 94 1C for 15 s, 55 1C for
30 s, and 68 1C for 8 min, followed by 25 cycles of 94 1C for 15 s,
55 1C for 30 s, and 68 1C for 8 min, with cumulative increments of
20 s at 68 1C with each successive cycle and a ﬁnal extension
period of 10 min at 68 1C. The ﬁrst round PCR products were then
utilized as templates for the second round PCR reactions under
the same conditions. PCR products were examined on 1% agarose
gels for amplicons 48 kb. The other approach consisted of
amplifying overlapping 50 (U5, gag-pol and vif) and 30 (pol, vif,
vpr, rev, vpu tat, env, nef and U3-R) half genomes. Ampliﬁcation
reactions were carried out in the presence of 1 High Fidelity
Platinum Taq PCR buffer, 0.2 mM of each primer, 2 mM Mg SO4,
0.2 mM each deoxynucleoside triphosphate and 0.025 u/ml of
Platinum Taq High Fidelity polymerase in 20 ul reactions (Invi-
trogen, Carlsbad, CA). The ﬁrst round PCR conditions were 94 1C
for 2 min, followed by 35 cycles of 94 1C for 20 s, 55 1C for 30 s,
and 68 1C for 5.50 min, followed by a ﬁnal extension of 68 1C for
5 min. For the second round of PCR, the total number of cycles
was increased to 37 and the annealing temperature changed from
55 1C to 58 1C. The 50 (1.U5.B1F/B5R1 and 2.U5.B4F/B5R2) and 30
(B3F1/1.R3B3R and B3F3/2.R3B6R) half genome primers used are
described elsewhere (Salazar-Gonzalez et al., 2009). The ampli-
cons were examined on precast 1% agarose 96-well E-gel. For both
approaches, the ﬁrst 30 nucleotides on the 50 end of the 9 kb/50-
half genomes and the last 30 nucleotides on the 30 end of the
9 kb/30-half genomes corresponded to internal nested primers
U5Cd/U5.B4F and 2.3030plCb/1.R3B6R, respectively, used during
the second round of PCR ampliﬁcation and were thus primer
derived. A separate PCR reaction was therefore carried out to
determine the precise viral nucleotides at these positions utilizing
the same cDNA aliquots used to obtain 50 half amplicons and
primers encompassing a 0.4 kb region from the 50 R (50-
GGTCTCTCTGGTTAGACCAGAT-30; nt 455-476) to gag (50-
TCCAGCTCCCTGCTTGCCCATACTA-30; nt 914-890). This enabled
the determination of the complete viral LTR sequence (U3-R-
U5), and subsequently, the complete 50 half (U3-R-U5, gag-pol
and vif) and 30 half (pol, vif, vpr, rev, vpu tat, env, nef and U3-R-
U5) genomes. Thus, the full-length HIV-1 genomes (U3-R-U5-HIV
genes–U3-R-U5) could be ascertained.
DNA sequencing and sequence alignment
DNA sequencing and sequence alignments were performed as
previously described (Bar et al., 2010; Keele et al., 2008, 2009;
J. Baalwa et al. / Virology 436 (2013) 33–4846Li et al., 2010; Salazar-Gonzalez et al., 2009). All sequences are
available under GenBank accession nos. JX202785–JX203216,
JX236668–JX236679 and JX877476–JX877521. Alignments are
available at (http://www.hiv.lanl.gov/content/sequence/HIV/USER_
ALIGNMENTS/Baalwa/).
Sequences, diversity analysis and phylogenetic inference of T/F
genomes
Sequences were aligned using Clustal W version 2.11 (Larkin
et al., 2007). Phylogenetic trees were constructed by maximum-
likelihood estimation using PhyML version 3.0 (Guindon et al.,
2010) or by the neighbor joining method using ClustalW (Larkin
et al., 2007). Maximum within patient sequence diversity was
determined by phylogenetic analysis using parsimony (PAUP)
version 4.0 (Rogers and Swofford, 1999). Subtype assignments
were based on the REGA (www.dbpartners.stanford.edu/RegaSub
typing/) and RIP (www.hiv.lanl.gov) tools and maximum like-
lihood phylogenetic tree analyses. Recombination breakpoint
locations were identiﬁed by SimPlot (Lole et al., 1999). Highlighter
plots (www.hiv.lanl.gov) were used to display nucleotide sub-
stitutions in the viral quasispecies as compared to the T/F
sequence. T/F sequences were inferred based on a model of early
random virus evolution as previously described (Keele et al.,
2008; Lee et al., 2009; Ochsenbauer et al., 2012; Salazar-
Gonzalez et al., 2009).
Generation of infectious molecular clones
To obtain IMCs corresponding to T/F viruses from subjects
191845, 9004SS, 190049, 191647, 191859, 191882, 191727,
191947 and 191982, each inferred T/F full-length genome was
chemically synthesized as three overlapping fragments contain-
ing unique restriction sites to allow concatenation (Blue Heron
Biotechnology). Additional restriction enzyme cleavage sites were
added to the 50 and 30 ends of the outermost fragments to
facilitate insertion into an appropriate cloning vector (pCR XL
TOPO or pBR322). This was followed by a one-step ligation of the
three viral DNA fragments into a cloning vector using T4 DNA
ligase (New England Biolabs Inc.).
To construct IMCs of T/F viruses from subjects R880F, R463F and
191084, overlapping 50 and 30 fragments containing complete LTR
elements at both genomic ends were ampliﬁed using proviral DNA as
the template. The antisense primer for the 50 fragment and the sense
primer for the 30 fragment were designed to lie downstream and
upstream, respectively, of a unique restriction enzyme site to allow
for generation of overlapping fragments that encompass this site. The
sense primer for the 50 fragment was designed to exactly anneal to
the beginning of the U3-R-U5 50 LTR and the antisense primer of the
30 fragment to exactly begin at the end of the U3-R-U5 30 LTR.
Fragments were ampliﬁed using bulk PCR as previously described
(Salazar-Gonzalez et al., 2009). Ampliﬁcation products were analyzed
for correct size by 1% agarose gel and the desired amplicons
subjected to another PCR reaction in 1 buffer, 0.2 mM of each
dNTP and Platinum Taq High Fidelity DNA polymerase (Invitrogen)
at 94 1C for 2 min followed by a single extension at 68 1C for 5 min to
add 30 adenine overhangs. Products were then puriﬁed by gel
extraction (Qiagen) with each genomic half being eluted indepen-
dently and T/A ligated into the pCR-XL TOPO vector (Invitrogen). The
ligation reactions were used to transform TOP-10 cells, which were
then plated on LB agar media containing 50 mg/ml kanamycin and
cultured overnight at 30 1C. For each genomic fragment, 20 to 100
single colonies were selected and grown overnight at 30 1C with
constant shaking at 225 rpm. Plasmid DNA with 50 and 30 fragments
identical to the T/F sequence were excised and linearized to allow for
a one step 3-piece DNA ligation with the appropriate vector.Phenotypic analyses
Infectious molecular clones were assessed for replication
competence, co-receptor usage and susceptibility to neutraliza-
tion by monoclonal and polyclonal antibodies and fusion inhibi-
tors. Viral stock generation, titrations, cell infections and
neutralization assays were carried out using 293T cells, TZM-bl
cells and activated primary human CD4þT-cells, as previously
described (Decker et al., 2005; Keele et al., 2008; Salazar-Gonzalez
et al., 2009). TZM-bl cells were obtained from the NIH AIDS
Research and Reference Reagent Program (catalogue #8129).
Coreceptor usage was determined using two different approaches.
First, replication competent IMC derived viruses were used to
infect TZM-bl cells in the presence of neither, either or both of the
CCR5 and CXCR4 selective inhibitors, TAK-779 and AMD3100
(NIH AIDS Research and Reference Reagent Program catalogue
#4983 and #8128). Second, use of CCR5 but not CXCR4 was
conﬁrmed by Env pseudovirus infection of NP2 cells expressing
CD4 and neither or either CCR5 or CXCR4. Neutralizing antibody
assays were conducted independently in two laboratories at the
University of Alabama at Birmingham (J.B.) and Duke University
(D.C.M.) using both IMCs and Env-pseudotyped HIV-1 virus stocks
as previously described (Keele et al., 2008; Salazar-Gonzalez et al.,
2009; Seaman et al., 2010; Wei et al., 2003). HIVIG-B is a pool of
puriﬁed IgG from HIV-1 subtype B chronically infected subjects.
HIVIG-C is a pool of puriﬁed IgG from six South African subjects
chronically infected by HIV-1 subtype C. High-titer, broadly
neutralizing serum IgG was also puriﬁed from three South African
subtype C infected subjects (SA-C62, SA-C72 and SA-C74) not
included in the HIVIG-C pool and these were tested individually.Competing interests
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